Results 171 to 180 of about 2,511,849 (258)

The efficacy of rosuvastatin to reduce circulating tissue factor extracellular vesicles after ovarian cancer surgery. [PDF]

Blood Adv
Osataphan S, Patell R, Babuta M, Rosovsky RP, Hisada Y, Edmiston C, Elavalakanar P, Pfeffer MA, Bregar A, Ramos A, Garrett L, Ren S, Neuberg D, Szabo G, Flaumenhaft R, Mackman N, Shea M, Zwicker JI.   +17 more
europepmc   +1 more source

Interferon beta drives therapy resistance in a patient‐derived model of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Interferon type 1 (IFN‐1) production and signaling is associated with the acquisition of therapy resistance, following chronic DNA damage, via Interferon‐related DNA damage resistance signature (IRDS) gene expression. An alternative, DNA damage‐independent role of sustained IFN‐1 mediated resistance was identified and characterized by the emergence of ...
Ashlyn Conant, Tise Suzuki, Kiera McGivney, V. S. S. Abhinav Ayyadevara, Sharon Asariah, Jay Deng, Ethan Nyein, Jacqueline Coats, Gary Yu, Yevgeniya J. Ioffe, Christian Hurtz, Juli J. Unternaehrer   +11 more
wiley   +1 more source

Tissue factor activity and 1-year mortality in patients with active cancer and acute ischemic stroke: findings from the SCAN study. [PDF]

Res Pract Thromb Haemost
Gon Y, Kawano T, Kitano T, Yamagami H, Abe S, Hashimoto H, Ohara N, Takahashi D, Abe Y, Takahashi T, Takasugi J, Kanki H, Sasaki T, Sakaguchi M.   +13 more
europepmc   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Tissue factor [PDF]

Science-Business eXchange, 2013
openaire   +1 more source

Tissue factor.

Blood & Vessel, 1987
KOBAYASHI, Norio, TANAKA, Hiroshi, ANDOH, Kiyoshi, UCHIYAMA, Toshimasa   +3 more
openaire   +2 more sources

Effect of therapeutic plasma exchange on tissue factor and tissue factor pathway inhibitor in septic shock. [PDF]

Crit Care
Stahl K, Lehner GF, Wendel-Garcia PD, Seeliger B, Pape T, Schmidt BMW, Schenk H, Schmitt J, Sauer A, Wild L, Peukert K, Putensen C, Bode C, Joannidis M, David S.   +14 more
europepmc   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source

Spatial biology in cancer epigenetics

Molecular Oncology, EarlyView.
Spatial epigenomics combines molecular profiling with tissue architecture to reveal how gene regulation is organized within intact tissues. In cancer, these technologies uncover the mechanisms driving tumor heterogeneity and microenvironmental interactions, opening new opportunities for biomarker discovery and precision medicine.
Eva Crespo‐García, Manel Esteller
wiley   +1 more source